PROLIGO.

PROLIGO, a subsidiary of Degussa AG, has expanded its production capacity for oligonucleotide synthesis in as well-as; not only-but also; not only-but; not alone-but the US and Japan. The of the present day capacity will support its primers and probes business, which includes a broad range of specialty oligonucleotides, including siRNA.
The company has built a just discovered state-of-the-art production facility in Boulder Colo and doubled capacity at its unit in Kyoto, Japan. The company declines to make notes on the investment cost or capacity figures for the sites.
The investments were readyed by increasing demand for its oligonucleotides, says

...